The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang, Chief Scientific Officer and Founder …
New patent for a novel diagnostic test to detect anti-microbial resistance filed, after successful completion of development and initial testing Oxford, 27th July 2022 Press Release – Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test Oxford Vacmedix (OVM), the UK clinical stage biopharma company, focused on the development of a new …
Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays. Project with Department of Oncology, University of Oxford and Reading Scientific Services (RSSL) to develop the methodology for T-cell potency assays of vaccines. Oxford, 25th May 2022 Press Release – Innovate UK funding for development of novel T-cell potency assays Oxford Vacmedix …
Dr Shisong Jiang recieved an invitation to the annual Royal Garden Party to recognise many years’ service to charity. Oxford, 23rd May 2022 Press Release – Dr Shisong Jiang invited to Buckingham Palace On Wednesday 18 May, the Dr Shisong Jiang, the founder and CSO of Oxford Vacmedix, was invited to Buckingham Palace in London …
Oxford Vacmedix founder Dr Shisong Jiang invited to Buckingham Place Read More »
A Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has started – the first clinical trial of a cancer vaccine using the novel technology. Press Release – Oxford group announces first patient treated with novel cancer vaccine Oxford, 4th November 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of …
Appointment brings in-depth expertise of company development and investment and enhanced contacts in Asia to Oxford Vacmedix Press Release – Appointment of Mr Choon-Yoon Lim as Director Oxford 19th October 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Mr. Chong-Yoon Lim as a …
Mr Chong-Yoon Lim of Hanmi Science appointed as a Director Read More »
Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 …
MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200 Read More »
Oxford Vacmedix UK Ltd announces the appointment of Mark Thomas as Head of Clinical Operations, bringing in-depth expertise in running clinical trials and in pharmaceutical development to Oxford Vacmedix. Press Release – appointment of Mark Thomas as Head of Clinical Operations Oxford, 14th June 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development …
Mark Thomas appointed as Head of Clinical Operations Read More »
Oxford Vacmedix UK Ltd announces the appointment of Dr Thomas Morris as Chief Medical Officer, bringing in-depth expertise in oncology clinical development to the Company. Press Release – Dr Thomas Morris appointed as Chief Medical Officer Oxford, 23rd March 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today …
Dr Thomas Morris appointed as Chief Medical Officer Read More »
Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Oxford, UK – 4th January 2020 – FOR IMMEDIATE RELEASE Press Release – OVM CHAIN Collaboration Oxford 4th Jan 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on …
Oxford Vacmedix and CHAIN Biotech collaborate to develop oral vaccines Read More »